48 results about "Carbohydrate antigen" patented technology

Compositions and methods for treating diseases associated with aberrant glycosylation of cell surface molecules and expression of tumor-associated carbohydrate antigens (TACAs) are provided. Also provided are fusion proteins having specificity for tumor-associated carbohydrate antigen (TACA) comprising a half-life extender molecule, vectors encoding the TACA-fusion proteins, and recombinant cells comprising the TACA-specific fusion proteins.

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-human carbohydrate antigen CA125 monoclonal antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.8-10. The monoclonal antibody provided by the invention can specifically recognize and bind to a natural carbohydrate antigen CA125 expressed by human cells or tissues, has good affinity and relatively high sensitivity of binding of the antibody and the antigen, has strong anti-interference ability to complex non-target protein components in the cells / tissues, is beneficial to significantly improving the accuracy and reliability of immunodetection of human CA125 protein, and has good application prospects. The method is suitable for high-specificity, high-sensitivity and high-reliability detection of the human CA125 protein, and has good applicability in a plurality of detection systems such as immunoblotting, immunoprecipitation, immunohistochemistry and the like.

Compositions and methods for treating diseases associated with aberrant glycosylation of cell surface molecules and expression of tumor-associated carbohydrate antigens (TACAs) are provided. Also provided are bispecific fusion proteins and chimeric antigen receptors (CARs) having specificity for tumor associated carbohydrate antigen (TACA-CAR), vectors encoding the TACA-bispecific fusion proteins and CARs, and recombinant cells comprising the TACA-bispecific fusion proteins and CARs.

The invention belongs to the technical field of novel functional materials and biosensing detection, and provides a preparation method and application of a pyrenyl-based covalent organic framework immunosensor. Specifically, a pyrenyl covalent organic framework is adopted as an electrochemiluminescence material, and free rotation of 1, 3, 6, 8-tetra (4-formylphenyl) pyrene is effectively inhibited through connection of formylhydrazine, so that non-radiative transition is weakened, and the electrochemiluminescence signal intensity is enhanced. The nickel-iron-carbon nano tube loaded with the gold nano particles is used as a substrate material, on one hand, the three-dimensional interconnected carbon nano tube can improve the electron transfer efficiency, and the large-area gold nano particles can immobilize more antibodies, and on the other hand, the uniformly dispersed iron-nickel active center can promote the generation of more tripropylamine free radicals with strong oxidizing property, so that the anti-tumor effect is improved. The luminous efficiency of the pyrenyl covalent organic framework is further improved. The carbohydrate antigen 242 is detected according to different electrochemical luminescence signal intensities of to-be-detected substances with different concentrations.

The invention relates to the technical field of albumin oligopeptides, in particular to a preparation method of albumin oligopeptides and application of the albumin oligopeptides in promotion of postoperative patient recovery. The albumin oligopeptide provided by the invention can be taken before, during or after an operation, not only can quickly promote postoperative recovery and reduce the content of total bilirubin and direct bilirubin of a patient, but also can reduce the activity of glutamic oxalacetic transaminase and glutamic-pyruvic transaminase, and also can reduce the activity of carbohydrate antigen 199 and the content of alpha fetoprotein. In addition, by taking the albumin oligopeptide, the bitter throat dryness can be improved, nausea and vomiting symptoms can be eliminated, and the albumin oligopeptide has the effect of promoting postoperative liver function recovery of obstructive jaundice.

The present invention relates to a cancer vaccine conjugate comprising a CRM197 carrier protein and an immunogenic peptide covalently linked to the residues C186 and 0201 of the CRM197 carrier by means of a linker. Suitable immunogenic peptides include glycopeptides, such as glycopeptides comprising a tumor associated carbohydrate antigen (TACA) (e.g., GalNAc, Galb (1, 3) GalNAc or Neu5Ac alpha (2-6) GalNAc). Cancer vaccine conjugates, methods of producing and uses thereof are provided.

The invention discloses an sEV mRNA combined marker for early diagnosis of pancreatic cancer, application of the sEV mRNA combined marker and a detection kit. The combined marker comprises NDRG4, AP1B1, ARPC1B and TBC1D9B. The invention further discloses a carbohydrate antigen CA19-9 in serum. The biomarkers NDRG4, AP1B1, ARPC1B and TBC1D9B and the carbohydrate antigen CA19-9 in serum are combined for diagnosing the pancreatic cancer, the problem that the sensitivity and specificity are insufficient when the CA19-9 is used for diagnosing and evaluating PDAC can be solved, the pancreatic cancer can be accurately and early diagnosed, and the kit has important guiding significance for prognosis of patients.

The present application relates to the field of chemiluminescent immunoassay, and specifically to water-soluble acridine sulfonamide derivatives, preparation methods, applications thereof, and kits. In some embodiments, the water-soluble acridine sulfonamide derivatives can label sulfhydryl groups under weakly alkaline or acidic conditions and are water-soluble, thereby being applicable to carbohydrate antigen detection.

The invention discloses an antibody for resisting carbohydrate antigen 199 and application of the antibody, and relates to the field of antibodies. The anti-carbohydrate antigen 199 antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of carbohydrate antigen 199, and has good activity.

The invention belongs to the technical field of quality control products of tumor markers such as carbohydrate antigens, and particularly relates to a liquid quality control product of tumor markers containing multiple carbohydrate antigens, which takes human serum as a matrix and comprises the following components: A, non-analytes including blocking proteins, B, non-analytes including C and D; the blocker is a functional protein obtained by modifying a blocker through fucosylation, and a fucose-containing sugar chain structure is introduced through enzymolysis and glycosylation, so that the blocker can specifically recognize a fucose-containing Si-Lea epitope shared by carbohydrate antigens; the B analyte comprises carbohydrate antigens and other markers, and the other markers comprise tumor markers and non-tumor related markers. Aiming at the problems of obvious cross reaction of carbohydrate antigens and insufficient stability of liquid quality control products, the invention provides a multi-component synergistic system taking blocker protein as a core, and high uniformity, stability and detection convenience of the liquid quality control products are realized by specifically combining carbohydrate antigen conserved epitopes and dynamically blocking the cross reaction.

The invention relates to the technical field of immunosensors, in particular to a Gd MOF composite material, an immunosensor and a preparation method and application of the immunosensor. The preparation method of the Gd MOF composite material comprises the following steps: dissolving polyether F127 in a mixed solvent, then adding gadolinium (Gd) salt and 5-aminoisophthalic acid (5-AIPA), and carrying out a first heating reaction to obtain Gd MOF; and dispersing the Gd MOF in a copper salt solution, and carrying out a second heating reaction to obtain the Gd MOF composite material. The invention also provides the double-ligand Gd MOF composite material prepared by adopting the method, an antibody-combined illuminant, an immunosensor and a preparation method of the double-ligand Gd MOF composite material. The invention provides a novel MOF material which is used for an ECL sensing system, and efficient detection of carbohydrate antigen 19-9 (CA19-9) is achieved.

The invention relates to the technical field of medical diagnosis and artificial intelligence aided decision making, and discloses a pancreatic cancer early screening method for people with new diabetes mellitus based on MUC2 pancreatic cancer cell exosome ACOT7. Detecting expression levels of three biomarkers, namely ACOT7 protein, MUC2 protein and serum carbohydrate antigen CA19-9, derived from pancreatic cancer cell exosomes in blood, inputting a pancreatic cancer risk assessment model based on a three-level sequential feature refining architecture, and outputting an integrated risk likelihood ratio; and finally generating a structured screening report containing hierarchical risk decision categories and clinical suggestions. According to the method, accurate, efficient and automatic early risk stratification of high-risk groups suffering from the pancreatic cancer with new diabetes mellitus is realized, and the early detection rate of the pancreatic cancer is remarkably improved.

The present invention belongs to the technical field of quality control products containing tumor markers such as carbohydrate antigens, and specifically relates to a liquid quality control product for tumor markers containing multiple carbohydrate antigens. The liquid quality control product uses human serum as a matrix and contains the following components: A non-analyte includes blocking protein, which is a functional protein modified by fucosylation of the blocking agent. The sugar chain structure containing fucose is introduced through enzymatic hydrolysis and glycosylation, so that it can specifically recognize the fucose-containing Si-Lea epitope shared by carbohydrate antigens; B analytes include carbohydrate antigens and other markers, and other markers include tumor markers and non-tumor-related markers. In response to the problems of significant cross-reaction of carbohydrate antigens and insufficient stability of liquid quality control products, the present invention provides a multi-component synergistic system with blocking protein as the core. By specifically binding to the conserved epitopes of carbohydrate antigens and dynamically blocking cross-reactions, high uniformity, stability and convenient detection of liquid quality control products are achieved.

The present invention relates to humanized anti-Lewis Y antibodies that specifically bind Lewis Y and do not show any cross-reactivity. In particular, the humanized anti-Lewis Y antibodies do not bind to Lewis b or any other blood group carbohydrate antigen. In particular, the present invention relates to humanized anti-Lewis Y antibodies for use in the treatment of cancer.

This invention relates to the field of biotechnology, and more particularly to a biomarker, kit, and application for the diagnosis of pancreatic malignant tumors. The biomarker comprises aldehyde-ketone reductase 1B10 protein and carbohydrate antigen 19-9 protein. This biomarker is a secreted serum protein that can specifically distinguish PDAC patients from normal individuals, and from individuals with benign pancreatic diseases, exhibiting high specificity without significant non-specific elevation interference. Combined detection with CA199 can synergistically enhance diagnostic efficacy, significantly reducing the rate of missed diagnoses and misdiagnoses. Simultaneously, this biomarker can assess the postoperative tumor resection effect in PDAC patients, predict whether curative resection is achieved, and provide an effective target for postoperative prognostic monitoring.

The present disclosure generally relates to improved methods for preparing glycoconjugates. The method includes conjugating a saccharide to a carrier protein using an acetoxyborohydride-containing reducing mixture prepared in situ.

The invention discloses a conjugate containing a trehalose derivative and a carbohydrate antigen as well as a preparation method and application of the conjugate, and belongs to the technical field of anti-tumor carbohydrate vaccines. The conjugate is obtained by taking an immunologic stimulant trehalose derivative of a mincle receptor as an embedded adjuvant to be conjugated with a sugar antigen TF, the trehalose derivative can improve the immunogenicity of the TF sugar antigen, the TF sugar antigen is presented to a corresponding immune cell, and a higher-titer immune response aiming at tumor sugar antigen TF specificity is generated. In addition, the compound also has the advantages of clear structure, simple and convenient synthesis method, stable and controllable product quality and the like, and can overcome the defect of weak immunogenicity of sugar antigens; meanwhile, under the action of an embedded adjuvant trehalose derivative, the vaccine can also generate immune memory.

The present invention discloses novel monoclonal antibodies and functional fragments thereof that specifically bind to SLeA carbohydrate antigen with high specificity and selectivity. The invention further provides compositions comprising the antibodies or fragments thereof as well as uses of the antibodies, fragments and compositions.

The invention relates to the technical field of early gastric cancer screening, and discloses a novel biomarker detection method for early gastric cancer screening, which comprises the following steps: S1, preparation before detection: performing joint detection on pepsinogen, gastritin-17, carcino-embryonic antigen and carbohydrate antigen 72-4, and preparing corresponding detection reagents and standard substances; s2, sample collection: adopting a disposable sterile blood taking needle and a vacuum tube, and extracting 3-5ml of venous blood through sterile operation; s3, sample treatment and storage: separating serum through a centrifugal machine, and after the treatment is completed, putting the sample into a storage device for storage; and S4, detection operation: preheating the detector, and then calibrating the detector by a standard product. In the invention, the pepsinogen, the gastritin-17, the carcino-embryonic antigen and the carbohydrate antigen 72-4 are jointly detected, so that the problem of low accuracy possibly caused by the fact that a marker detection method is mostly adopted in the existing early gastric cancer screening is solved.

The invention relates to a conjugate of a dual agonist and a carbohydrate antigen, the conjugate contains the dual agonist and the carbohydrate antigen, the dual agonist is an iNKT cell agonist and a mincle receptor agonist, the iNKT cell agonist is an alpha-galactosylceramide analogue, and the mincle receptor agonist is a trehalose derivative; the structural general formula of the conjugate is as shown in formula (I): # imgabs0 # X is a carbohydrate antigen, and Y is a linker. The vaccine prepared from the conjugate can activate iNKT cells and mincle receptors at the same time, induce generation of high-titer IgG antibodies and effectively improve the immunogenicity of carbohydrate antigens, and has a good anti-tumor application prospect.

Provided herein are enzymatic compositions for carbohydrate antigen cleavage, methods, uses, devices and systems related thereto. Specifically, the compositions comprise two enzymes, GalNAc deacetylase and galactosaminidase, and the compositions may also comprise a crowding agent. In addition, it was found that the compositions described herein are active at temperatures and pH levels suitable for cell survival.

The application provides a kit for detecting sialylated carbohydrate antigen KL-6 and a use method and application thereof, and relates to the field of in vitro detection. The kit for detecting sialylated carbohydrate antigen KL-6 provided by the application comprises magnetic beads, KL-6 antibodies, acridinium ester, a magnetic bead storage solution, an acridinium ester storage solution, a sample processing solution, a pre-priming solution and a priming solution. The sample processing solution comprises, in terms of mass fraction, 0.03-0.3% polyoxyethylene fatty acid ester, 0.3-2.0% bovine serum albumin, 0.3-2.0% raffinose, 0.3%-2.0% sodium hydroxide, 0.01-1.5% NaN3 and 0.3-1.5% sodium chloride, the rest is purified water, and the pH is 8-10. The kit can be used for determining sialylated carbohydrate antigen KL-6 in serum, and has high accuracy and strong anti-interference ability.

The invention relates to a sensor based on supramolecular calixarene and a preparation method and application thereof. Comprising calixarene and a fluorescent indicator, and the molar ratio of the calixarene to the fluorescent indicator is 1: (3.5-4.5). The calixarene is tert-butyl calixarene (BFT) or calixarene monoboric acid derivative (BFTPS), and the fluorescent indicator is 6, 7-dihydroxy coumarin. The invention also provides a preparation method of the sensor and application of the sensor in detection of carbohydrate antigens, glycoproteins, cancer cells and serum. The calixarene used in the invention has a unique three-dimensional cavity molecular structure, and can selectively adsorb guest molecules of different sizes. Then calixarene is modified, boric acid derivatization groups are introduced, calixarene mono-boric acid derivatives are used as host molecules, XDS is used as a fluorescent indicator, and the sensor based on the supramolecular calixarene is formed and can be used for detecting biological samples such as carbohydrate antigens, glycoproteins, cancer cells and serum.

Provided are compositions and methods for treating diseases associated with aberrant glycosylation of cell surface molecules and expression of tumor-associated carbohydrate antigens (TACA). Also provided are fusion proteins specific to tumor-associated carbohydrate antigens (TACA) comprising a half-life extender molecule, vectors encoding the TACA-fusion proteins, and recombinant cells comprising the TACA-specific fusion proteins.

The invention discloses an antibody for resisting carbohydrate antigen 199 and application of the antibody, and relates to the field of antibodies. The anti-carbohydrate antigen 199 antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of carbohydrate antigen 199, and has good activity.

The present invention relates to glycoconjugates, glycoconjugate immunogens and glycoconjugate vaccines comprising carbohydrate antigens coupled to immunogenic carrier proteins, or materials for detecting and screening the resulting antibodies. Improved methods for more directly and accurately conjugating carbohydrate antigens to free thiol groups of immunogenic carrier proteins are described, including "click chemistry" methods based on photocatalyzed thiol-ene reactions.

Provided herein are enzymatic compositions for carbohydrate antigen cleavage, methods, uses, apparatuses and sys-O tems associated therewith. In particular, the composition comprises two enzymes, GalNAcDeacetylase and Galactosaminidase and the el composition may further comprise a crowding agent. Furthermore, the compositions described herein were found to have activity a C) temperatures and pH levels suitable for cell viability.

Provided herein are enzymatic compositions for carbohydrate antigen cleavage, methods, uses, devices, and systems related thereto. In particular, the composition comprises two enzymes of GalNAc deacetylase and galactosaminase, and the composition can further comprise a crowding agent. In addition, it was found that the compositions described herein have activity at temperatures and pH levels suitable for cell survival.

This invention belongs to the fields of immunology and molecular biology, specifically relating to a nanobody targeting the sialylated glycan antigen (KL-6) and its applications. The nanobody comprises any one of five sets of complementary determinant regions. This invention also provides a nucleic acid molecule encoding the nanobody, a carrier and host cell containing the nucleic acid molecule, a fusion protein and conjugate containing the nanobody, and a pharmaceutical composition containing the above substances. The nanobody of this invention exhibits high specificity and affinity, and can be used to prepare KL-6 detection reagents, in vivo imaging probes, or therapeutic products, particularly showing broad application prospects in the diagnosis and treatment of KL-6-related diseases such as interstitial lung disease.

The present invention discloses a disialoganglioside GD2 affinity peptide and its applications. The affinity peptide YQAF-X sequence is: COOH-Tyr-Gly-Tyr-His-X1-X2-Arg-NH2. Gangliosides are overexpressed in human tumors such as lung cancer, brain cancer, melanoma, etc., and have an impact on the EGFR signaling pathway. GANGLIOSIDE can be used as a carbohydrate antigen to treat cancer. The YQAF-X series of polypeptides can bind to tumor cells with high expression of GANGLIOSIDE, and in vivo optical imaging and results confirm excellent imaging results for various tumors. The tumor detection reagent and surgical navigation imaging agent prepared based on the YQAF-X series can be better applied to early tumor screening, early tumor diagnosis, and intraoperative navigation of tumor surgery.